Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 4/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381374 | 0.87 | TDP1 (0.43) | FOLH1KMT2A | |
| SCHEMBL31384213 | 0.86 | NOD1 (0.52) | NOD1ALBFOLH1GLP1R | |
| SCHEMBL22473457 | 0.85 | SLC6A5 (0.44) | FOLH1KMT2A | |
| SCHEMBL15498944 | 0.83 | CAPN1 (0.44) | ALBKMT2A | |
| SCHEMBL25542908 | 0.80 | NOD1 (0.58) | NOD1GLP1RLPAR3 | |
| SCHEMBL25542893 | 0.80 | NOD1 (0.58) | NOD1GLP1RLPAR3 | |
| SCHEMBL19308433 | 0.80 | NOD1 (0.58) | NOD1GLP1RLPAR3 | |
| SCHEMBL25542898 | 0.80 | NOD1 (0.58) | NOD1GLP1RLPAR3 | |
| SCHEMBL16264552 | 0.80 | NOD1 (0.58) | NOD1GLP1RLPAR3 | |
| SCHEMBL25542862 | 0.80 | NOD1 (0.58) | NOD1GLP1RLPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |